stockrow
Friday 6 November 2026
Export IMVT’s income statement to Excel — free account
Immunovant, Inc.
IMVT Healthcare Biotechnology
- EPS
- −5.63%
- Free cash flow
- −5.96%
Quarter to June 2026, against a year earlier
30.53
2.14
+7.54%
Follow IMVT
Alert me
Immunovant, Inc. (IMVT) Total debt
Immunovant, Inc.'s total debt at the end of fiscal 2023 was $1.6M, down 38.1% from $2.5M in fiscal 2022. At the end of the quarter to 30 September 2023 it was $614.0K. Over the past ten years it has ranged from $300.0K (fiscal 2018) to $3.4M (fiscal 2021); the current reading is higher than 40% of that period. Immunovant, Inc. ranks 415th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2023 | $1.6M | (38.07%) |
| FY2022 | $2.5M | (25.81%) |
| FY2021 | $3.4M | 7.12% |
| FY2020 | $3.2M | 963.33% |
| FY2018 | $300.0K | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $614.0K | (33.19%) |
| Jun 2023 | $919.0K | (41.46%) |
| Mar 2023 | $1.6M | 3.90% |
| Dec 2022 | $1.5M | (16.01%) |
| 8 more quarters | Free account |
Against its own ten years
Low $300.0K
High $3.4M
Ten-year median
$2.5M
Current reading's percentile
40
Total debt against peers
| Company | Total debt |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $2.8B |
| IONS Ionis Pharmaceuticals, Inc. compare | $1.4B |
| MIRM Mirum Pharmaceuticals, Inc. compare | $731.3M |
| LGND Ligand Pharmaceuticals Incorporated compare | $679.9M |
| KOD Kodiak Sciences Inc. compare | $174.5M |
| CGON CG Oncology, Inc. compare | $3.0M |
| IMVT Immunovant, Inc. | $614.0K |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| MANE Veradermics Incorporated compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt